Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06441747
Title Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Australasian Gastro-Intestinal Trials Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS


No variant requirements are available.